Recent clinical studies show that chimeric antigen receptor (CAR) T cells, best known for treating B cell malignancies, can be used to treat patients with various B cell-driven autoimmune diseases. Here, the authors update us with the progress so far and the considerations for further improving and extending their therapeutic application.
- James B. Chung
- Jennifer N. Brudno
- James N. Kochenderfer
